Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNotes PayablesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Onconetix (ONCO) Cash & Equivalents (2023 - 2025)

Historic Cash & Equivalents for Onconetix (ONCO) over the last 3 years, with Q3 2025 value amounting to $836556.0.

  • Onconetix's Cash & Equivalents rose 14496.87% to $836556.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $836556.0, marking a year-over-year increase of 14496.87%. This contributed to the annual value of $646500.0 for FY2024, which is 8580.47% down from last year.
  • Onconetix's Cash & Equivalents amounted to $836556.0 in Q3 2025, which was up 14496.87% from $300000.0 recorded in Q2 2025.
  • Over the past 5 years, Onconetix's Cash & Equivalents peaked at $21.3 million during Q1 2023, and registered a low of $300000.0 during Q2 2025.
  • In the last 3 years, Onconetix's Cash & Equivalents had a median value of $1.6 million in 2025 and averaged $4.7 million.
  • In the last 5 years, Onconetix's Cash & Equivalents tumbled by 9553.83% in 2024 and then skyrocketed by 14496.87% in 2025.
  • Onconetix's Cash & Equivalents (Quarter) stood at $4.6 million in 2023, then tumbled by 85.8% to $646500.0 in 2024, then rose by 29.4% to $836556.0 in 2025.
  • Its last three reported values are $836556.0 in Q3 2025, $300000.0 for Q2 2025, and $1.6 million during Q1 2025.